Headlines

BSA filed for Chapter 11 bankruptcy in February amid the threat of thousands of potential lawsuits brought by former scouts who allege they were sexually abused while in Scouting. Many survivors allege the organization concealed their sexual abuse, often times for years, instead of alerting law enforcement and…

Charleston Mayor John Tecklenburg declared Sept. 26, 2020 as Mesothelioma Awareness Day. The occasion marked the 9th year that the City recognized the day following a request from Motley Rice.

Consumer misuse is a common defense used by corporations when accused of producing dangerous and defective products. In a new article, Motley Rice attorneys Anne McGinness Kearse and Taylor Lacy discuss keeping attention on the defective product and the harm it caused by anticipating such arguments.

Michigan state officials have agreed to pay $600 million to the residents of Flint, Michigan to resolve legal claims against the state for causing the contamination of Flint’s water supply with lead and other harmful substances. The water crisis, which garnered international attention, killed at least a dozen people…

The settlement will resolve tens of thousands of women’s claims that Essure caused severe health problems and/or fetal death.

A mid-air collision claimed seven lives in Soldotna, Alaska, on July 31, 2020, including four members of a South Carolina family.

Legal online publication Law360 recognized medical attorney Ann E. Rice Ervin as one of five 2020 Rising Stars in the area of product liability.

A $192 million settlement was approved today to resolve shareholder claims that alleged SCANA Corp. and certain of the energy company’s executives violated the Securities Exchange Act.

Updates to the label for Elmiron®, a medication used to treat bladder pain and inflammation, now warn of potential, permanent damage to the retina that could cause irreversible vision loss.

The U.S. Food and Drug Administration sent a warning letter to Allergan, now AbbVie, reprimanding the medical device manufacturer for serious deficiencies in Allergan’s post-approval studies of its recalled breast implants, which have been linked to an increased risk of cancer.